SEATTLE, UNITED STATES, UNITED STATES, February 4, 2022 /EINPresswire.com/ -- New Research Study "Middle East Tapentadol Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share and Outlook" has been added to Coherent Market Insights.

Rising cases of pain-associated with various chronic diseases such diabetic neuropathy and cancer combined unavailability of efficient substitute therapy for management of neuropathic pain is expected to boost the Middle East Tapentadol market over the forecast period. Janssen Pharmaceutical sold its license of marketing and distribution of the U.S. to Depomed, Inc. and in April 2017, Depomed, Inc. won the patent for tapentadol. Three ongoing clinical trials for tapentadol are being carried on for various indications and age groups.

Request For A Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/1054

Furthermore, promising results obtained from clinical trials is expected to augment the tapentadol market growth in the near future. Currently, the regulatory authorities have approved tapentadol only for consumption by adults and is not prescribed for children due to its high therapeutic efficacy. However, one in three clinical trials are subjected to pediatric use. Grünenthal GmbH is carrying out an open-label trial, enrolling subjects aged 6 years to 18 years, which is estimated to be completed in December 2018. Another trial by St. Olavs Hospital is for pre- and post-operative pain relief after primary knee arthroplasty with estimated study completion year 2021.

Tapentadol is also used for other applications and has been found to be the safest and the first-line of treatment choice for advanced chronic kidney disease. Regardless of that, clinical trials are still needed to be prescribed for the same. Moreover, various pilot studies have been conducted in the National Center for Biotechnology Information. Increasing off-label applications for this moderately addictive drug along with low competition for existing indications, and robust pipeline is expected to boost growth of the Middle East tapentadol market over the forecast period.

Detailed Segmentation:

Middle East Tapentadol Market, By Therapeutic Application:

Pain Management
Neuropathic Pain
Cancer Pain
Others
Cough Treatment

Middle East Tapentadol Market, By Countries:
KSA
Country Trends and Estimation (US$ Million)*
UAE
Bahrain
Oman
Qatar
Israel
Iran

Company Profiles

Depomed, Inc.*
Janssen Pharmaceutical, Inc.
Grünenthal
Allergan, Plc.

Get PDF Brochure of this Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1054

Key Takeaways

• High prevalence of pain-related diseases in countries such as Iran, Palestine, and Kingdom of Saudi Arabia. For instance, according to Journal of Taibah University Medical Sciences, the prevalence of diabetic neuropathic pain in Iran was 51.90% in 2016.

• Promising results of clinical trials of tapentadol are expected to boost the Middle East tapentadol market over the forecast period.

• Unavailability of generic drugs after patent win by Depomed, Inc. in 2016, has abolished the competition

• Less likelihood of tough competition from any other opioid for neuropathic pain and absence of any other opioid therapy under research is expected to support growth of the market

Reasons To Buy This Report:

• It provides an analysis of the evolving competitive landscape.
• It provides analytical data together with strategic planning methods to help businesses make informed decisions.
• It helps in the comprehension of the most important product groups.
• market dynamics such as drivers, restraints, trends, and opportunities are discussed by researchers.
• It includes regional analysis of the Middle East Tapentadol Market, as well as corporate profiles of a variety of stakeholders.

Buy This Complete Business Report With Flat USD 2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1054

Mr.Abhijit
Coherent Market Insights
+1 2067016702
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.